Click Here to return To Results

 

Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide Arch Int Med 151:1573-1578, Vance,M.L.&Harris,A.G., 1991 See this aricle in Pubmed Article Abstract The clinical response rate was 88%,irrespective of dosage or treatment duration.Serum growth hormone levels decreased in 172(94%)of 182 patients and IGF-I levels decreased in 91(92%)of 99.The mean pretreatment growth hormone level was 39.4+/-4.4ug/L and decreased to 12.2+/-1.5ug/L.Growth hormone levels decreased to less than 5 ug/L in 82(45%)of 182 patients.The pretreatment IGF-I level was 5.62+/-0.41U/mL and decreased to 2.64+/-0.19 U/mL;suppression to 2U/mL or lower occurred in 46(46%)of 99 patients.The degree of growth hormone suppression was associated with longer treatment duration but not with the total octreotide dosage per day.In 34 patients studied prospectively,pituitary tumor size decreased by greater than 20%in 15(44%).Side effects occurred in 37%of patients and were most commonly transient loose acholic stools,pain at the injection site,and abdominal discomfort;severity was mild to moderate.Glucose tolerance was unchanged or improved in 52%and declined in 48%of 25 patients evaluated.Octreotide is an effective treatment for acromegaly that may be used as primary therapy or after surgery and/or pituitary irradiation.

Related Tags

(click to filter results - removes previous filter) acromegaly adverse drug reaction neoplasm,pituitary neoplasm,pituitary,treatment of octreotide somatostatin analogue treatment of neurologic disorder

Click Here to return To Results